Bokf Na Sells 2,922 Shares of DaVita Inc. $DVA

Bokf Na trimmed its holdings in shares of DaVita Inc. (NYSE:DVA) by 37.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,837 shares of the company’s stock after selling 2,922 shares during the quarter. Bokf Na’s holdings in DaVita were worth $550,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Elevation Wealth Partners LLC grew its stake in shares of DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after acquiring an additional 165 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of DaVita during the 2nd quarter worth approximately $43,000. iSAM Funds UK Ltd bought a new position in shares of DaVita during the 3rd quarter worth approximately $46,000. Stance Capital LLC bought a new position in shares of DaVita during the 3rd quarter worth approximately $47,000. Finally, Camelot Portfolios LLC bought a new position in shares of DaVita during the 4th quarter worth approximately $57,000. 90.12% of the stock is owned by institutional investors.

DaVita Trading Up 1.1%

NYSE DVA opened at $198.39 on Friday. The company has a market cap of $12.74 billion, a PE ratio of 18.40, a PEG ratio of 0.65 and a beta of 0.84. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $199.27. The stock has a 50 day moving average of $153.03 and a 200-day moving average of $132.70.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter last year, the firm posted $2.00 EPS. The company’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on DVA. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and raised their price target for the stock from $126.00 to $220.00 in a research note on Wednesday. Truist Financial raised their price target on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research note on Friday. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Finally, TD Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $187.83.

Key DaVita News

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported Q1 results that topped expectations, with adjusted EPS of $2.87 versus consensus near $2.33 and revenue of $3.42 billion above estimates. The company also lifted its 2026 EPS guidance, reinforcing confidence in the earnings outlook. DaVita (DVA) Is Up 27.6% After Boosting 2026 EPS Guidance On Strong Q1 Results
• Positive Sentiment: UBS raised its price target on DaVita to $235 from $190 and kept a Buy rating, signaling further upside potential after the post-earnings rally. UBS Group Issues Positive Forecast for DaVita (NYSE:DVA) Stock Price
• Positive Sentiment: Multiple Zacks articles highlighted DaVita as a Strong Buy value stock and pointed to improving earnings estimate revisions, which can attract momentum and value investors. Surging Earnings Estimates Signal Upside for DaVita HealthCare (DVA) Stock
• Positive Sentiment: Seeking Alpha said DaVita was upgraded to Buy after strong Q1 results, improved volumes, and a favorable valuation profile, supporting the case that the stock can continue to outperform. DaVita: Improved Volumes And Tech In Focus (Rating Upgrade)
• Neutral Sentiment: DaVita also announced participation in the BofA Securities 2026 Health Care Conference, which may keep the company in front of investors but is not a direct operating catalyst. DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.